Floatz logo

Imatinib

Solid Tumor Cancer

China Medical University HospitalSmall moleculePhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

42 Active assets in the Solid Tumor Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
Sarcoma Oncology Research Center, LLC
Phase 2CCC
Zofran
GlaxoSmithKline
Phase 3CCC
DEXAMETHASONE
GlaxoSmithKline
Phase 3CCC
Casopitant
GlaxoSmithKline
Phase 3CCC
MITOMYCIN C
Sarcoma Oncology Research Center, LLC
Phase 2CCC

View all 50 →

Same molecule, other indications

Imatinib is also rated in:

chronic myeloid leukemiaDormant
BB
Indicative ·
71 / 100
View asset →
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
71 / 100
View asset →
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →